Adams et al.

Application No.: 09/177,711

Page 9

VI. Conclusion

Applicants believe that the foregoing comprises a full and complete response to the Office Action of record. Accordingly, favorable reconsideration and subsequent allowance of all pending claims is earnestly solicited.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 925-472-5000.

Respectfully submitted,


Joseph R. Snyder Reg. No. 39,381

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, 8th Floor San Francisco, California 94111-3834

Tel: (415) 576-0200 Fax: (415) 576-0300

JS:fcr

WC 9036054 v2



engorgeable tissue is decreased.

WC 9036054 v2

6

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE CLAIMS:

Claims 60 and 70 have been amended as follows:

1	60. (Amended) A method of decreasing pain associated with use of
2	prostaglandins for treatment of erectile tissue dysfunction comprising administering to a
3	subject in need of prostaglandin at least one NO producing agent at a low dose which
4	does not produce significant systemic side effects [so that] but which decreases pain
5	associated with prostaglandin use [sensed by nociceptive tissue in close proximity to
5	engorgeable genital tissue is decreased].
l	70. (Amended) A method of decreasing pain associated with use of
2	prostaglandins for treatment of erectile tissue dysfunction comprising administering to a
3	subject in need of prostaglandin at least one agent at a low dose which does not produce
4	significant systemic side effects [that] but which augments action of cGMP so that pain
5	associated with prostaglandin use sensed by nociceptive tissue in close proximity to